This lecture is part 2 of 3 delivered by Dr Mason at the Low Carbohydrate Down Under Gold Coast conference in October 2022. Dr Mason exposes the devastating damages brought on by the first cholesterol decreasing drug, Triparanol, and the guilty decision that followed.
This is followed by a short history of statins, consisting of the high rates of cancer in test animals seen with the first statin to come to market, and the massive (+$ 1,000,000,000) legal payouts made to settle suits from statin adverse effects.
Particular statin negative effects, including dementia are covered, followed by a close analysis of the quantifiable benefits that might be credited to statins. This consists of an evaluation of a recent paper co-authored by David Diamond, Ben Bikman and Paul Mason that talks about how to identify who is most likely and not likely to take advantage of statin therapy utilizing triglyceride and LDL levels.
Dr Paul Mason acquired his medical degree with honours from the University of Sydney. He is likewise a fellow of the Australasian College of Sports and Workout Physicians, holds a Bachelor's degree in Physiotherapy and a Masters degree in Occupational Health. He is currently Chief Medical Officer of the Defeat Diabetes program, an evidence-based program focussed on way of life management of metabolic health problems, consisting of type 2 diabetes.
Please think about supporting Low Carb Down Under by means of Patreon. A small monthly contribution will help in the costs of shooting and modifying these presentations and will allow us to keep producing high quality material free from advertising. For more information check out;